Surpassing the emerging immune-checkpoint inhibitor market

dc.contributor.author	Vitek, Michael P
dc.date.accessioned	2018-02-01T15:54:21Z
dc.date.available	2018-02-01T15:54:21Z
dc.date.issued	2016-01
dc.identifier	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000375484400149&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=47d3190e77e5a3a53558812f597b0b92
dc.identifier.eissn	2326-6074
dc.identifier.issn	2326-6066
dc.identifier.uri	https://hdl.handle.net/10161/16044
dc.publisher	American Association for Cancer Research
dc.relation.ispartof	CANCER IMMUNOLOGY RESEARCH
dc.relation.isversionof	10.1158/2326-6074.CRICIMTEATIAACR15-A092
dc.title	Surpassing the emerging immune-checkpoint inhibitor market
dc.type	Journal article
pubs.author-url	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000375484400149&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=47d3190e77e5a3a53558812f597b0b92
pubs.issue	1
pubs.organisational-group	Clinical Science Departments
pubs.organisational-group	Duke
pubs.organisational-group	Neurology
pubs.organisational-group	Neurology, Behavioral Neurology
pubs.organisational-group	School of Medicine
pubs.publication-status	Published
pubs.volume	4

Files

Now showing 1 - 1 of 1